5Canadian Institute for Health Information. Drug Expenditure in Canada :1985 to 2007[Z]. Ottawa:Canadian Institute for Health Information, 2008. 3--36.
6Marchildon GP .Health Systems in Transition : Canada [M] . Toronto: University of Toronto Press, 2006: 1--17.
7Patented Medicine Prices Review Board.Annual Rport 2007[R] . Ottawa: Patented Medicine Prices Review Board, 2008: 2--62.
8Patented Medicine Prices Review Board. A Description of the Laspeyres Methodology Used to Construct the Patented Medicine Price Index [ Z] . 1997.
5Edward C Mansley,Norman V Carroll,Kristina S Chen, et al. Good Research Practices for Mea- suring Drug Costs in Cost- effec- tiveness Analyses: a Managed Care Perspective: the Ispor Drug Cost Task Force Report--part Iii [J].Value in Health,2010,13(01).
6Robert Navarro.Managed Care Pharmacy Practice [M].[S.1.]: Jones & Bartlett Learning,2009.
7Claude Le Lilliu.What criteria pen, G Priol, H for pharmaceu- ticals reimbursement?[J].The Euro-pean Journal of Health Eco- nomics, 2003,4(01 ).
8Livio Garattini,Dante Cor- nago, Paola De compadri.Pricing and Reimbursement of In-patent Drugs in Seven European Coun- tries: a Comparative Analysis [J]. Health Policy, 2007,82(03).
9M Filko,P Szilagyiova.CASE3 THE SLOVAK EXPERIENCE IN THE INTERNATIONAL PRICE BENCHMARKING FOR PRESCRIPTION DRUGS[J].Value in Health.2009(7)
